Asset Details
Do you wish to reserve the book?
Eosinophil Cationic Protein (ECP), a predictive marker of bullous pemphigoid severity and outcome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Eosinophil Cationic Protein (ECP), a predictive marker of bullous pemphigoid severity and outcome
Do you wish to request the book?
Eosinophil Cationic Protein (ECP), a predictive marker of bullous pemphigoid severity and outcome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Eosinophil Cationic Protein (ECP), a predictive marker of bullous pemphigoid severity and outcome
2017
Overview
Bullous Pemphigoid (BP) is an inflammatory rare autoimmune bullous dermatosis, which outcome cannot be predicted through clinical investigations. Eosinophils are the main immune infiltrated cells in BP. However, the release of Major Basic Protein (MBP), Eosinophil Derived Neurotoxin (EDN), and Eosinophil Cationic Protein (ECP) upon eosinophil activation has still not been evaluated with respect to BP development. MBP, EDN and ECP were measured by ELISA in serum (n = 61) and blister fluid (n = 20) of patients with BP at baseline, and in serum after 2 months of treatment (n = 41). Eosinophil activation in BP patients was illustrated at baseline by significantly higher MBP, EDN and ECP serum concentrations as compared with control subjects (n = 20), but without distinction according to disease severity or outcome. EDN and ECP values were even higher in the blister fluids (
P
< 0.01 and
P
< 0.05, respectively), whereas MBP values were lower (
P
< 0.001). ECP serum concentration decreased after 60 days of treatment in BP patients with ongoing remission but not in patients who later relapsed (
P
< 0.05). A reduction of at least 12.8 ng/mL in ECP concentrations provided a positive predictive value for remission of 81%, showing that ECP serum variation could be a useful biomarker stratifying BP patients at risk of relapse.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 82/80
/ 96/21
/ Aged
/ Anti-Inflammatory Agents - therapeutic use
/ Cell Movement - drug effects
/ Clobetasol - therapeutic use
/ Enzyme-linked immunosorbent assay
/ Eosinophil Cationic Protein - blood
/ Eosinophil Cationic Protein - genetics
/ Eosinophil Cationic Protein - immunology
/ Eosinophil Major Basic Protein - blood
/ Eosinophil Major Basic Protein - genetics
/ Eosinophil Major Basic Protein - immunology
/ Eosinophil-Derived Neurotoxin - blood
/ Eosinophil-Derived Neurotoxin - genetics
/ Eosinophil-Derived Neurotoxin - immunology
/ Female
/ Humanities and Social Sciences
/ Humans
/ Male
/ Pemphigoid, Bullous - diagnosis
/ Pemphigoid, Bullous - drug therapy
/ Pemphigoid, Bullous - genetics
/ Pemphigoid, Bullous - immunology
/ Proteins
/ Science
